Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 6:01PM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced that
Bassil Dahiyat, Ph.D., president and chief executive officer, will
present at the 42nd Annual J.P. Morgan Healthcare Conference on
January 10, 2024 at 3:45 p.m. PST.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website located at www.xencor.com. After the webcast, a
replay will be archived on the website for at least 30 days.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103100031/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Xencor (NASDAQ:XNCR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024